NO20051641L - Improved imaging agents comprising barbituric acid derivatives - Google Patents

Improved imaging agents comprising barbituric acid derivatives

Info

Publication number
NO20051641L
NO20051641L NO20051641A NO20051641A NO20051641L NO 20051641 L NO20051641 L NO 20051641L NO 20051641 A NO20051641 A NO 20051641A NO 20051641 A NO20051641 A NO 20051641A NO 20051641 L NO20051641 L NO 20051641L
Authority
NO
Norway
Prior art keywords
imaging
imaging agents
barbituric acid
acid derivatives
improved imaging
Prior art date
Application number
NO20051641A
Other languages
English (en)
Inventor
Klaus Kopka
Hans-Jorg Breyholz
Stefan Wagner
Michael Schafers
Bodo Levkau
Benedictc Guilbert
Duncan Wynn
Original Assignee
Amersham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Plc filed Critical Amersham Plc
Publication of NO20051641L publication Critical patent/NO20051641L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelsen angår diagnostiske avbildingsmidler for in vivo avbilding. Avbildingsmidlene omfatter et syntetisk barbitursyrederivat merket i 5-posisjon med en avbildingsdel som egner seg for diagnostisk avbilding in vivo. Oppfinnelsen tilveiebringer også fannasøytiske og radiofarmasøytiske sammensetninger som omfatter avbildingsmidlene, sammen med utstyrene for fremstilling av radiofarmasøytika. Videre er det beskrevet chelator -konjugater av barbitursyrederivatet, som egner seg for fremstilling av avbildingsmidler som omfatter et radioaktivt eller paramagnetisk metallion. Avbildingsmidlene er nyttige for diagnostisk avbilding in vivo av forskjellige sykdomstilstander, inkludert aterosklerose.
NO20051641A 2002-10-08 2005-04-04 Improved imaging agents comprising barbituric acid derivatives NO20051641L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223249.4A GB0223249D0 (en) 2002-10-08 2002-10-08 Improved imaging agents
PCT/GB2003/004351 WO2004032936A1 (en) 2002-10-08 2003-10-08 Improved imaging agents comprising barbituric acid derivatives

Publications (1)

Publication Number Publication Date
NO20051641L true NO20051641L (no) 2005-06-02

Family

ID=9945439

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051641A NO20051641L (no) 2002-10-08 2005-04-04 Improved imaging agents comprising barbituric acid derivatives

Country Status (10)

Country Link
US (1) US20060120956A1 (no)
EP (1) EP1549317A1 (no)
JP (1) JP2006505550A (no)
CN (1) CN1720050A (no)
AU (1) AU2003273505B2 (no)
CA (1) CA2501136A1 (no)
GB (1) GB0223249D0 (no)
NO (1) NO20051641L (no)
RU (1) RU2005109272A (no)
WO (1) WO2004032936A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
GB0612333D0 (en) * 2006-06-21 2006-08-02 Ge Healthcare Ltd Radiopharmaceutical products
US10328164B2 (en) 2006-06-21 2019-06-25 Ge Healthcare Limited Radiopharmaceutical products
US8529874B2 (en) * 2007-05-16 2013-09-10 Ge Healthcare As Peptide imaging agents
GB0718386D0 (en) * 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
GB201115937D0 (en) 2011-09-14 2011-10-26 Univ Aberdeen 18F-labelled compounds for use as positron emission imaging agents
CA3109419A1 (en) * 2018-08-24 2020-02-27 Xeniopro GmbH Novel compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952971A (en) * 1971-11-09 1976-04-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Airfoil shape for flight at subsonic speeds
US3952091A (en) * 1974-10-23 1976-04-20 Hoffmann-La Roche Inc. Simultaneous multiple radioimmunoassay
GB1527416A (en) * 1976-07-20 1978-10-04 Ciba Geigy Ag Photopolymerisible diepoxides
US6472227B1 (en) * 1986-06-04 2002-10-29 Abbott Laboratories Barbiturate assay, tracers, immunogens, antibodies and kit
US5102786A (en) * 1987-05-21 1992-04-07 Pb Diagnostic Systems, Inc. Biological diagnostic assay system
KR100660509B1 (ko) * 1998-05-15 2006-12-22 지이 헬쓰케어 리미티드 표지된 글루타민 및 라이신 유사체
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
EP1309579B1 (en) * 2000-05-30 2005-10-12 Board Of Governors Of Wayne State University Inhibitors of matrix metalloproteinases
KR20030061825A (ko) * 2000-10-26 2003-07-22 화이자 프로덕츠 인크. 피리미딘-2,4,6-트리온 메탈로프로테이나제 억제제
WO2002034753A2 (en) * 2000-10-26 2002-05-02 Pfizer Products Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
WO2002047701A1 (en) * 2000-12-12 2002-06-20 Angiolab, Inc. Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
GB0115929D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase electrophilic fluorination

Also Published As

Publication number Publication date
RU2005109272A (ru) 2006-01-27
AU2003273505B2 (en) 2007-04-19
GB0223249D0 (en) 2002-11-13
WO2004032936A1 (en) 2004-04-22
US20060120956A1 (en) 2006-06-08
AU2003273505A1 (en) 2004-05-04
EP1549317A1 (en) 2005-07-06
CN1720050A (zh) 2006-01-11
CA2501136A1 (en) 2004-04-22
JP2006505550A (ja) 2006-02-16

Similar Documents

Publication Publication Date Title
NO20051641L (no) Improved imaging agents comprising barbituric acid derivatives
IL175667A (en) Imaging factor that includes a synthetic caspase-3 inhibitor marked with the neuroimaging agent, a radiopharmaceutical containing it, a kit for preparation of the preparation and a method for diagnosis based on it
BR9611533A (pt) Lipopoliamina composição e utilização e processo de preparação de uma lipopoliamina
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
BRPI0507824A (pt) hidroxiapatita, processo para a preparação de um particulado de hidroxiapatita marcada com radionuclìdeo, composição farmacêutica, uso de hidroxiapatita e de um radionuclìdeo emissor de alfa ou um radionuclìdeo emissor de beta, dispositivo, e, método de tratamento radioquìmico de um ser humano ou de um indivìduo animal não humano necessitando do mesmo
NO931631D0 (no) Kompleksdannende midler og maalsoeking av radioaktive immunoreagenser nyttige innen terapeutiske og diagnostiske bildedannende sammensetninger og fremgangsmetoder
CY1112401T1 (el) Παραγωγα πυριδαζινης
MXPA04009435A (es) Derivados de quinolina y quinolinona radiomarcados y su uso como ligandos de receptor de glutamato metabotropico.
DE3773237D1 (de) Einen makrozyklischen koordinat und einen antikoerper enthaltende konjugatverbindung.
NO20021205D0 (no) Faste lipid formuleringer
HK1081884A1 (en) Radiolabeled conjugates based on substance p and the uses thereof
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
BR0210965A (pt) Conjugado de quelador, complexo de radiometal, radiofármaco, kit para a preparação do mesmo, composto, e, processo para a preparação do mesmo
EP2316493A3 (en) Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
EP1813607A3 (en) Tetraaza- or N2S2- complexants, and their use in radiodiagnostics or radiotherapy
CY1107028T1 (el) Παραγωγα ινδανυλ-πιπεραζινων μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
EE200200281A (et) Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks
EP1968606A4 (en) PREPARATION OF PHARMACEUTICAL SALTS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC ACID
AU2002350950A1 (en) Compounds for imaging alzheimer's disease
BRPI0408848A (pt) formulações orais de cladribine
NO20004273L (no) Streptograminderivater, deres fremstilling samt preparater inneholdende forbindelsene
BR0315578A (pt) Composição de complexo de tecnécio, produto radiofarmacêutico, kit para a preparação do produto radiofarmacêutico de tecnécio, e, método de formação de imagem de diagnóstico de trombos
TW200740428A (en) Substituted propanamide derivatives and pharmaceutical compositions thereof
DK1359943T3 (da) Biotinderivater og deres konjugater med chelateringsmidler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application